The identification of galaxies at extreme distances provides the most direct information about the earliest phases of galaxy formation. But at redshifts z > 5 even the most luminous galaxies appear faint; the interpretation of low signal-to-noise ratio data is difficult and misidentifications do occur. Here we report optical and near-infrared observations of the source STIS123627+621755, which was previously suggested to be at a redshift of 6.68 (ref. 1). At that redshift, and with the reported spectral energy distribution, the galaxy should be essentially invisible at wavelengths less than 9,300 A, because the intervening intergalactic medium absorbs almost all light energetic enough to ionize neutral hydrogen--that is, with wavelengths less than the redshifted Lyman limit of lambda = (1 + z) x 912A. At near-infrared wavelengths, however, the galaxy should be relatively bright. Here we report a detection of the galaxy at 6,700 A and a non-detection at a wavelength of 1.2 microm, contrary to expectations for z approximately 6.68. The data conservatively require that STIS123627+621755 has a redshift z < 6.

Download full-text PDF

Source
http://dx.doi.org/10.1038/35046027DOI Listing

Publication Analysis

Top Keywords

galaxy
5
evidence redshift
4
redshift galaxy
4
galaxy stis123627+621755
4
stis123627+621755 identification
4
identification galaxies
4
galaxies extreme
4
extreme distances
4
distances direct
4
direct earliest
4

Similar Publications

Stable-isotope resolved metabolomics (SIRM) is a powerful approach for characterizing metabolic states in cells and organisms. By incorporating isotopes, such as C, into substrates, researchers can trace reaction rates across specific metabolic pathways. Integrating metabolomics data with gene expression profiles further enriches the analysis, as we demonstrated in our prior study on glioblastoma metabolic symbiosis.

View Article and Find Full Text PDF

Background: Early literature on the Woven EndoBridge (WEB) device reported 80-90% adequate aneurysm occlusion but low complete occlusion (40-55%). It is uncertain whether residual or recurrent aneurysms require re-treatment to prevent future rupture.

Objective: To systematically review the literature to meta-analyze occlusion and complication rates after re-treatment of these aneurysms.

View Article and Find Full Text PDF

Clinical metaproteomics reveals host-microbiome interactions underlying diseases. However, challenges to this approach exist. In particular, the characterization of microbial proteins present in low abundance relative to host proteins is difficult.

View Article and Find Full Text PDF

The James Webb Space Telescope has discovered a surprising population of bright galaxies in the very early Universe (≲500 Myr after the Big Bang) that is hard to explain with conventional galaxy-formation models and whose physical properties are not fully understood. Insight into their internal physics is best captured through nebular lines, but at these early epochs, the brightest of these spectral features are redshifted into the mid-infrared and remain elusive. Using the mid-infrared instrument onboard the James Webb Space Telescope, here we present a detection of Hα and doubly ionized oxygen ([O iii] 4959,5007 Å) from the bright, ultra-high-redshift galaxy candidate GHZ2/GLASS-z12.

View Article and Find Full Text PDF

Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.

Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!